NCT06685276
- Conditions
- Colorectal Cancer Metastatic
- Locations
-
- China PLAGH Beijing, China
Clinical trial condition
Colorectal Cancer Metastatic
Explore clinical trials studying Colorectal Cancer Metastatic. Study availability and eligibility vary by location and protocol.
145 public trials
49 recruiting studies
Colorectal Cancer Metastatic trial results
NCT04854213
- Conditions
- Colorectal Cancer Metastatic, Neoplasm Metastasis, Neoplasms, +3 more
- Locations
-
- Istituto Nazionale Tumori - Fondazione G. Pascale Naples, NAPOLI, Italy
NCT06663839
- Conditions
- Colonic Diseases, Colorectal Cancer Metastatic, Colorectal Neoplasms, +9 more
- Locations
-
- Hospital Universitari Vall d'Hebron Barcelona, Spain
- START Madrid-FJD, Hospital Fundación Jiménez Díaz Madrid, Spain
NCT06547203
- Conditions
- Colonic Diseases, Colorectal Cancer Metastatic, Colorectal Neoplasms, +9 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
NCT03488953
- Conditions
- Colorectal Cancer Metastatic, Liver Metastases
- Locations
-
- Jena University Hospital Jena, Germany
- University Hospital Tübingen Tübingen, Germany
NCT06440902
- Conditions
- Colorectal Cancer Metastatic
- Locations
-
- Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China
NCT05068531
- Conditions
- Colonic Diseases, Colorectal Cancer Metastatic, Colorectal Neoplasms, +9 more
- Locations
-
- Centre hospitalier de l'Université de Montréal (CHUM) Montreal, Quebec, Canada
Recruiting
Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study
NCT06018714
- Conditions
- Colonic Diseases, Colorectal Cancer Metastatic, Colorectal Neoplasms, +9 more
- Locations
-
- Colorectal Department,SunYat-sen University Cancer Center Guangzhou, Guangdong, China
NCT05501353
- Conditions
- Colonic Diseases, Colorectal Cancer Metastatic, Colorectal Neoplasms, +9 more
- Locations
-
- the Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China
Enrolling by Invitation
The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer
NCT06959589
- Conditions
- Colorectal Cancer Metastatic, KRAS G12C Mutation
- Locations
-
- The Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou, Zhejiang, China